A Randomized, Single Center, Double Blind, Two Treatment, Two-Period, Crossover Glucose Clamp Study To Test For Bioequivalence Between Wockhardtâ??s Consegnaâ?¢ - 30/70 (Bi Phasic Isophane Insulin 30/70 Injection 200 IU) and MixtardÂ® 30/70 (100 IU), In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Insulin-lispro/Insulin-suspension-isophane (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Wockhardt Ltd
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Dec 2017 New trial record